newsfilter
← Latest News
Business Wire·

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or